Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'fluorodopa' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 91 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Antonini, A; Moresco, RM; Gobbo, C; De Notaris, R; Panzacchi, A; Barone, P; Calzetti, S; Negrotti, A; Pezzoli, G; Fazio, F
      The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT

      NEUROLOGICAL SCIENCES
    2. Pal, PK; Lee, CS; Samii, A; Schulzer, M; Stoessl, AJ; Mak, EK; Wudel, J; Dobko, T; Tsui, JKC
      Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [F-18]-DOPA Ki

      PARKINSONISM & RELATED DISORDERS
    3. Pal, PK; Wszolek, ZK; Kishore, A; de la Fuente-Fernandez, R; Sossi, V; Uitti, RJ; Dobko, T; Stoessl, AJ
      Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene)

      PARKINSONISM & RELATED DISORDERS
    4. Cumming, P; Munk, OL; Doudet, D
      Loss of metabolites from monkey striatum during PET with FDOPA

      SYNAPSE
    5. Danielsen, EH; Smith, D; Hermansen, F; Gjedde, A; Cumming, P
      Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo

      SYNAPSE
    6. Rinne, JO; Nurmi, E; Ruottinen, HM; Bergman, J; Eskola, O; Solin, O
      [F-18]FDOPA and [F-18]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease

      SYNAPSE
    7. Ruottinen, HM; Niinivirta, M; Bergman, J; Oikonen, V; Solin, O; Eskola, O; Eronen, E; Sonninen, P; Rinne, UK
      Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging

      SYNAPSE
    8. Stoessl, AJ
      Assessing the integrity of the dopamine system in Parkinson's disease: Howbest to do it?

      MOVEMENT DISORDERS
    9. Nurmi, E; Ruottinen, HM; Bergman, J; Haaparanta, M; Solin, O; Sonninen, P; Rinne, JO
      Rate of progression in Parkinson's disease: A 6-[F-18]fluoro-L-dopa PET study

      MOVEMENT DISORDERS
    10. Cordato, NJ; Halliday, GM; McCann, H; Davies, L; Williamson, P; Fulham, M; Morris, JGL
      Corticobasal syndrome with tau pathology

      MOVEMENT DISORDERS
    11. Nakamura, T; Dhawan, V; Chaly, T; Fukuda, M; Ma, YL; Breeze, R; Greene, P; Fahn, S; Freed, C; Eidelberg, D
      Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease

      ANNALS OF NEUROLOGY
    12. Jaaskelainen, SK; Rinne, JO; Forssell, H; Tenovuo, O; Kaasinen, V; Sonninen, P; Bergman, J
      Role of the dopaminergic system in chronic pain - a fluorodopa-PET study

      PAIN
    13. Bruck, A; Portin, R; Lindell, A; Laihinen, A; Bergman, J; Haaparanta, M; Solin, O; Rinne, JO
      Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus

      NEUROSCIENCE LETTERS
    14. Stover, NP; Watts, RL
      Corticobasal degeneration

      SEMINARS IN NEUROLOGY
    15. Peigneux, P; Salmon, E; Garraux, G; Laureys, S; Willems, S; Dujardin, K; Degueldre, C; Lemaire, C; Luxen, A; Moonen, G; Franck, G; Destee, A; Van der Linden, M
      Neural and cognitive bases of upper limb apraxia in corticobasal degeneration

      NEUROLOGY
    16. Racette, BA
      Welding-related parkinsonism: Clinical features, treatment, and pathophysiology - Reply

      NEUROLOGY
    17. Dietz, M; Harder, S; Graff, J; Kunig, G; Vontobel, P; Leenders, KL; Baas, H
      Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[F-18]levodopa positron emission tomography in patients with Parkinson's disease

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    18. Kaasinen, V; Nurmi, E; Bruck, A; Bergman, J; Solin, O; Rinne, JO
      Increased frontal [F-18]fluorodopa uptake in early Parkinson's Disease: sex differences in the prefrontal cortex

      BRAIN
    19. Cumming, P; Danielsen, EH; Vafaee, M; Falborg, L; Steffensen, E; Sorensen, JC; Gillings, N; Bender, D; Marthi, K; Andersen, F; Munk, O; Smith, D; Moller, A; Gjedde, A
      Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts

      ACTA NEUROLOGICA SCANDINAVICA
    20. Hirono, N; Ishii, K; Sasaki, M; Kitagaki, H; Hashimoto, M; Imamura, T; Tanimukai, S; Hanihara, T; Kazui, H; Mori, E
      Features of regional cerebral glucose metabolism abnormality in corticobasal degeneration

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    21. Calne, DB
      Parkinson's disease is not one disease

      PARKINSONISM & RELATED DISORDERS
    22. Shinotoh, H; Uchida, Y; Ito, H; Hattori, T
      Relationship between striatal [I-123]beta-CIT binding and four major clinical signs in Parkinson's disease

      ANNALS OF NUCLEAR MEDICINE
    23. Frucht, S; Fahn, S; Chin, S; Dhawan, V; Eidelberg, D
      Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration

      MOVEMENT DISORDERS
    24. Laihinen, A; Ruottinen, H; Rinne, JO; Haaparanta, M; Bergman, J; Solin, O; Koskenvuo, M; Marttila, R; Rinne, UK
      Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [F-18]6-fluorodopa PET

      JOURNAL OF NEUROLOGY
    25. de la Fuente-Fernandez, R; Pal, PK; Vingerhoets, FJG; Kishore, A; Schulzer, M; Mak, EK; Ruth, TJ; Snow, BJ; Calne, DB; Stoessl, AJ
      Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

      JOURNAL OF NEURAL TRANSMISSION
    26. de la Fuente-Fernandez, R; Kishore, A; Calne, DB; Ruth, TJ; Stoessl, AJ
      Nigrostriatal dopamine system and motor lateralization

      BEHAVIOURAL BRAIN RESEARCH
    27. Chang, CW; Wang, HE; Lin, HM; Chtsai, CS; Chen, JB; Liu, RS
      Robotic synthesis of 6-[F-18]fluoro-L-dopa

      NUCLEAR MEDICINE COMMUNICATIONS
    28. Snow, BJ; Vingerhoets, FJG; Langston, JW; Tetrud, JW; Sossi, V; Calne, DB
      Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    29. DeJesus, OT; Haaparanta, M; Solin, O; Nickles, RJ
      6-FluoroDOPA metabolism in rat striatum: time course of extracellular metabolites

      BRAIN RESEARCH
    30. Seibyl, JP
      Single-photon emission computed tomography of the dopamine transporter in parkinsonism

      JOURNAL OF NEUROIMAGING
    31. Ernst, M; Zametkin, AJ; Jons, PH; Matochik, JA; Pascualvaca, D; Cohen, RM
      High presynaptic dopaminergic activity in children with Tourette's disorder

      JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
    32. Deep, P; Dagher, A; Sadikot, A; Gjedde, A; Cumming, P
      Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

      SYNAPSE
    33. Brown, WD; DeJesus, OT; Pyzalski, RW; Malischke, L; Roberts, AD; Shelton, SE; Uno, H; Houser, WD; Nickles, RJ; Holden, JE
      Localization of trapping of 6-[F-18]fluoro-L-m-tyrosine, an aromatic L-amino acid decarboxylase tracer for PET

      SYNAPSE
    34. Cumming, P; Yokoi, F; Chen, AJ; Deep, P; Dagher, A; Reutens, D; Kapczinski, F; Wong, DF; Gjedde, A
      Pharmacokinetics of radiotracers in human plasma during positron emission tomography

      SYNAPSE
    35. Trenkwalder, C; Walters, AS; Hening, WA; Chokroverty, S; Antonini, A; Dhawan, V; Eidelberg, D
      Positron emission tomographic studies in restless legs syndrome

      MOVEMENT DISORDERS
    36. Torstenson, R; Tedroff, J; Hartvig, P; Fasth, KJ; Langstrom, B
      A comparison of C-11-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system

      JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
    37. Kim, YH; Kim, JW; Ito, KG; Lim, HS; Cheong, HK; Kim, JY; Shin, YC; Kim, KS; Moon, YH
      Idiopathic parkinsonism with superimposed manganese exposure: Utility of positron emission tomography

      NEUROTOXICOLOGY
    38. Samii, A; Markopoulou, K; Wszolek, ZK; Sossi, V; Dobko, T; Mak, E; Calne, DB; Stoessl, AJ
      PET studies of parkinsonism associated with mutation in the alpha-synuclein gene

      NEUROLOGY
    39. Brown, WD; Taylor, MD; Roberts, AD; Oakes, TR; Schueller, MJ; Holden, JE; Malischke, LM; DeJesus, OT; Nickles, RJ
      FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa

      NEUROLOGY
    40. Rabasseda, X
      Perspectives in the treatment of Parkinson's disease: COMT inhibitors openup new treatment strategies

      DRUGS OF TODAY
    41. TANJI H; NAGASAWA H; ARAKI T; ONODERA J; TAKASE S; ITOH M; ITOYAMA Y
      PET STUDY OF STRIATAL FLUORODOPA UPTAKE AND DOPAMINE D-2 RECEPTOR-BINDING IN A PATIENT WITH JUVENILE PARKINSONISM

      European journal of neurology
    42. LEGER G; GJEDDE A; KUWABARA H; GUTTMAN M; CUMMING P
      EFFECT OF CATECHOL-O-METHYLTRANSFERASE INHIBITION ON BRAIN UPTAKE OF [F-18] FLUORODOPA - IMPLICATIONS FOR COMPARTMENTAL MODELING AND CLINICAL USEFULNESS

      Synapse
    43. DOUDET DJ; CHAN GLY; HOLDEN JE; MCGEER EG; AIGNER TA; WYATT RJ; RUTH TJ
      6-[F-18]FLUORO-L-DOPA PET STUDIES OF THE TURNOVER OF DOPAMINE IN MPTP-INDUCED PARKINSONISM IN MONKEYS

      Synapse
    44. CUMMING P; GJEDDE A
      COMPARTMENTAL ANALYSIS OF DOPA DECARBOXYLATION IN LIVING BRAIN FROM DYNAMIC POSITRON EMISSION TOMOGRAMS

      Synapse
    45. DOLLE F; DEMPHEL S; HINNEN F; FOURNIER D; VAUFREY F; CROUZEL C
      6-[F-18]FLUORO-L-DOPA BY RADIOFLUORODESTANNYLATION - A SHORT AND SIMPLE SYNTHESIS OF A NEW LABELING PRECURSOR

      Journal of labelled compounds & radiopharmaceuticals
    46. ERNST M; ZAMETKIN AJ; MATOCHIK JA; JONS PH; COHEN RM
      DOPA DECARBOXYLASE ACTIVITY IN ATTENTION-DEFICIT HYPERACTIVITY DISORDER ADULTS - A [FLUORINE-18]FLUORODOPA POSITRON EMISSION TOMOGRAPHIC STUDY

      The Journal of neuroscience
    47. ANTONINI A; MOELLER JR; NAKAMURA T; SPETSIERIS P; DHAWAN V; EIDELBERG D
      THE METABOLIC ANATOMY OF TREMOR IN PARKINSONS-DISEASE

      Neurology
    48. Taniwaki, T; Yamada, T; Yoshida, T; Sasaki, M; Kuwabara, Y; Nakagawa, M; Mihara, F; Motomura, S; Shigetou, H; Kira, J
      Heterogeneity of glucose metabolism in corticobasal degeneration

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    49. MORRISH PK; RAKSHI JS; BAILEY DL; SAWLE GV; BROOKS DJ
      MEASURING THE RATE OF PROGRESSION AND ESTIMATING THE PRECLINICAL PERIOD OF PARKINSONS-DISEASE WITH [F-18] DOPA PET

      Journal of Neurology, Neurosurgery and Psychiatry
    50. MORRISH PK; RAKSHI JS; BROOKS DJ
      CAN THE NEUROPROTECTIVE EFFICACY OF AN AGENT EVER BE CONCLUSIVELY PROVEN

      European journal of neurology
    51. DAOCASTELLANA MH; PAILLEREMARTINOT ML; HANTRAYE P; ATTARLEVY D; REMY P; CROUZEL C; ARTIGES E; FELINE A; SYROTA A; MARTINOT JL
      PRESYNAPTIC DOPAMINERGIC FUNCTION IN THE STRIATUM OF SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    52. RUOTTINEN HM; RINNE JO; OIKONEN VJ; BERGMAN JR; HAAPARANTA MT; SOLIN OH; RUOTSALAINEN UH; RINNE UK
      STRIATAL B-[F-18]FLUORODOPA ACCUMULATION AFTER COMBINED INHIBITION OFPERIPHERAL CATECHOL-O-METHYLTRANSFERASE AND MONOAMINE-OXIDASE TYPE-B - DIFFERING RESPONSE IN RELATION TO PRESYNAPTIC DOPAMINERGIC DYSFUNCTION

      Synapse
    53. MORRISH PK
      PARKINSONS-DISEASE IS NOT A LONG-LATENCY ILLNESS

      Movement disorders
    54. VINGERHOETS FJG; SCHULZER M; CAINE DB; SNOW BJ
      WHICH CLINICAL SIGN OF PARKINSONS-DISEASE BEST REFLECTS THE NIGROSTRIATAL LESION

      Annals of neurology
    55. CALNE DB; DELAFUENTEFERNANDEZ R; KISHORE A
      CONTRIBUTIONS OF POSITRON EMISSION TOMOGRAPHY TO ELUCIDATING THE PATHOGENESIS OF IDIOPATHIC PARKINSONISM AND DOPA-RESPONSIVE DYSTONIA

      Journal of neural transmission. Supplementum
    56. CUMMING P; GJEDDE A; REITH J
      CONTROVERSIES ARISING FROM RECENT FDOPA ARTICLES

      The Journal of nuclear medicine
    57. DEJESUS OT; ENDRES CJ; SHELTON SE; NICKLES RJ; HOLDEN JE
      EVALUATION OF FLUORINATED M-TYROSINE ANALOGS AS PET IMAGING AGENTS OFDOPAMINE NERVE-TERMINALS - COMPARISON WITH 6-FLUORODOPA

      The Journal of nuclear medicine
    58. RUOTTINEN HM; RINNE JO; HAAPARANTA M; SOLIN O; BERGMAN J; OIKONEN VJ; JARVELA I; SANTAVUORI P
      [F-18] FLUORODOPA PET SHOWS STRIATAL DOPAMINERGIC DYSFUNCTION IN JUVENILE NEURONAL CEROID-LIPOFUSCINOSIS

      Journal of Neurology, Neurosurgery and Psychiatry
    59. ANTONINI A; LEENDERS KL; VONTOBEL P; MAGUIRE RP; MISSIMER J; PSYLLA M; GUNTHER I
      COMPLEMENTARY PET STUDIES OF STRIATAL NEURONAL FUNCTION IN THE DIFFERENTIAL-DIAGNOSIS BETWEEN MULTIPLE SYSTEM ATROPHY AND PARKINSONS-DISEASE

      Brain
    60. SJOHOLM H; MELLGREN SI; SUNDSFJORD J
      NIGRO-STRIATAL DEGENERATION DEMONSTRATED IN PARKINSONIAN-PATIENTS WITH IODINE-123-BETA-CIT SPECT - METHODS OF QUANTITATION

      Acta neurologica Scandinavica
    61. YOST Y; CONWAY T
      SYNTHESIS AND PRELIMINARY EVALUATION OF (S)-(2-[F-18]FLUORO-4,5-DIHYDROXYPHENYL)-2-METHYL L-ALANINE, (S)-[F-18]-FMEDOPA, A POTENTIALLY IMPROVED IMAGING AGENT FOR THE PRESYNAPTIC DOPAMINERGIC NERVOUS-SYSTEM

      Nuclear medicine and biology
    62. HUME SP; LAMMERTSMA AA; MYERS R; RAJESWARAN S; BLOOMFIELD PM; ASHWORTH S; FRICKER RA; TORRES EM; WATSON I; JONES T
      THE POTENTIAL OF HIGH-RESOLUTION POSITRON EMISSION TOMOGRAPHY TO MONITOR STRIATAL DOPAMINERGIC FUNCTION IN RAT MODELS OF DISEASE

      Journal of neuroscience methods
    63. VINGERHOETS FJG; SCHULZER M; RUTH TJ; HOLDEN JE; SNOW BJ
      REPRODUCIBILITY AND DISCRIMINATING ABILITY OF FLUORINE-18-6-FLUORO-L-DOPA PET IN PARKINSONS-DISEASE

      The Journal of nuclear medicine
    64. ISHIKAWA T; DHAWAN V; CHALY T; MARGOULEFF C; ROBESON W; DAHL JR; MANDEL F; SPETSIERIS P; EIDELBERG D
      CLINICAL-SIGNIFICANCE OF STRIATAL DOPA DECARBOXYLASE ACTIVITY IN PARKINSONS-DISEASE

      The Journal of nuclear medicine
    65. POEWE WH; WENNING GK
      THE NATURAL-HISTORY OF PARKINSONS-DISEASE

      Neurology
    66. NAGASAWA H; TANJI H; ITOYAMA Y; SAITO H; KIMURA I; FUJIWARA T; IWATA R; ITOH M; IDO T
      BRAIN 6-[F-18]FLUORODOPA METABOLISM IN EARLY AND LATE-ONSET OF PARKINSONS-DISEASE STUDIED BY POSITRON EMISSION TOMOGRAPHY

      Journal of the neurological sciences
    67. MORRISH PK; SAWLE GV; BROOKS DJ
      REGIONAL CHANGES IN [F-18] DOPA METABOLISM IN THE STRIATUM IN PARKINSONS-DISEASE

      Brain
    68. BOECKER H; WEINDL A; LEENDERS K; ANTONINI A; KUWERT T; KRUGGEL F; VONEINSIEDEL HG; CONRAD B
      SECONDARY PARKINSONISM DUE TO FOCAL SUBSTANTIA-NIGRA LESIONS - A PET STUDY WITH [F-18] FDG AND [F-18] FLUORODOPA

      Acta neurologica Scandinavica
    69. SAWLE GV
      LIVING NEUROCHEMISTRY - THE DOPAMINERGIC SYSTEM

      Seminars in the neurosciences
    70. RINNE JO; LAIHINEN A; NAGREN K; RUOTTINEN H; RUOTSALAINEN U; RINNE UK
      PET EXAMINATION OF THE MONOAMINE TRANSPORTER WITH [C-11] BETA-CIT AND[C-11] BETA-CFT IN EARLY PARKINSONS-DISEASE

      Synapse
    71. KISH SJ; ZHONG XH; HORNYKIEWICZ O; HAYCOCK JW
      STRIATAL 3,4-DIHYDROXYPHENYLALANINE DECARBOXYLASE IN AGING - DISPARITY BETWEEN POSTMORTEM AND POSITRON EMISSION TOMOGRAPHY STUDIES

      Annals of neurology
    72. RUOTTINEN HM; RINNE JO; RUOTSALAINEN UH; BERGMAN JR; OIKONEN VJ; HAAPARANTA MT; SOLIN OH; LAIHINEN AO; RINNE UK
      STRIATAL [F-18] FLUORODOPA UTILIZATION AFTER COMT INHIBITION WITH ENTACAPONE STUDIED WITH PET IN ADVANCED PARKINSONS-DISEASE

      Journal of neural transmission
    73. EIDELBERG D; MOELLER JR; ISIKAWA T; DHAWAN V; SPETSIERIS P; CHALY T; ROBESON W; DAHL JR; MARGOULEFF D
      ASSESSMENT OF DISEASE SEVERITY IN PARKINSONISM WITH FLUORINE-18-FLUORODEOXYGLUCOSE AND PET

      The Journal of nuclear medicine
    74. LEE CS; SCHULZER M; MAK E; HAMMERSTAD JP; CALNE S; CALNE DB
      PATTERNS OF ASYMMETRY DO NOT CHANGE OVER THE COURSE OF IDIOPATHIC PARKINSONISM - IMPLICATIONS FOR PATHOGENESIS

      Neurology
    75. EIDELBERG D; MOELLER JR; ISHIKAWA T; DHAWAN V; SPETSIERIS P; CHALY T; BELAKHLEF A; MANDEL F; PRZEDBORSKI S; FAHN S
      EARLY DIFFERENTIAL-DIAGNOSIS OF PARKINSONS-DISEASE WITH F-18 FLUORODEOXYGLUCOSE AND POSITRON EMISSION TOMOGRAPHY

      Neurology
    76. RINNE JO; LAIHINEN A; RUOTTINEN H; RUOTSALAINEN U; NAGREN K; LEHIKOINEN P; OIKONEN V; RINNE UK
      INCREASED DENSITY OF DOPAMINE D2 RECEPTORS IN THE PUTAMEN, BUT NOT INTHE CAUDATE-NUCLEUS IN EARLY PARKINSONS-DISEASE - A PET STUDY WITH [C-11] RACLOPRIDE

      Journal of the neurological sciences
    77. MORRISH PK; SAWLE GV; BROOKS DJ
      CLINICAL AND [F-18] DOPA PET FINDINGS IN EARLY PARKINSONS-DISEASE

      Journal of Neurology, Neurosurgery and Psychiatry
    78. CUMMING P; ASE A; DIKSIC M; HARRISON J; JOLLY D; KUWABARA H; LALIBERTE C; GJEDDE A
      METABOLISM AND BLOOD-BRAIN CLEARANCE OF L-3,4-DIHYDROXY-[H-3]PHENYLALANINE ([H-3]DOPA) AND 6-[F-18]FLUORO-L-DOPA IN THE RAT

      Biochemical pharmacology
    79. ANTONINI A; VONTOBEL P; PSYLLA M; GUNTHER I; MAGUIRE PR; MISSIMER J; LEENDERS KL
      COMPLEMENTARY POSITRON EMISSION TOMOGRAPHIC STUDIES OF THE STRIATAL DOPAMINERGIC SYSTEM IN PARKINSONS-DISEASE

      Archives of neurology
    80. VINGERHOETS FJG; SNOW BJ; TETRUD JW; LANGSTON JW; SCHULZER M; CALNE DB
      POSITRON EMISSION TOMOGRAPHIC EVIDENCE FOR PROGRESSION OF HUMAN MPTP-INDUCED DOPAMINERGIC LESIONS

      Annals of neurology
    81. ADAM MJ; LU JM; JIVAN S
      STEREOSELECTIVE SYNTHESIS OF 3-O-METHYL-6-[F-18]FLUORODOPA VIA FLUORODESTANNYLATION

      Journal of labelled compounds & radiopharmaceuticals
    82. LEMAIRE C; DAMHAUT P; PLENEVAUX A; COMAR D
      ENANTIOSELECTIVE SYNTHESIS OF 6-[FLUORINE-18]-FLUORO-L-DOPA FROM NO-CARRIER-ADDED FLUORINE-28-FLUORIDE

      The Journal of nuclear medicine
    83. VINGERHOETS FJG; SNOW BJ; SCHULZER M; MORRISON S; RUTH TJ; HOLDEN JE; COOPER S; CALNE DB
      REPRODUCIBILITY OF FLUORINE-18-6-FLUORODOPA POSITRON EMISSION TOMOGRAPHY IN NORMAL HUMAN-SUBJECTS

      The Journal of nuclear medicine
    84. SAWLE GV; BURN DJ; MORRISH PK; LAMMERTSMA AA; SNOW BJ; LUTHRA S; OSMAN S; BROOKS DJ
      THE EFFECT OF ENTACAPONE (OR-611) ON BRAIN [F-18] 6-L-FLUORODOPA METABOLISM - IMPLICATIONS FOR LEVODOPA THERAPY OF PARKINSONS-DISEASE

      Neurology
    85. MARTIN WRW; PERLMUTTER JS
      ASSESSMENT OF FETAL TISSUE-TRANSPLANTATION IN PARKINSONS-DISEASE - DOES PET PLAY A ROLE

      Neurology
    86. CUMMING P; KUWABARA H; GJEDDE A
      A KINETIC-ANALYSIS OF 6-[F-18]FLUORO-L-DIHYDROXYPHENYLALANINE METABOLISM IN THE RAT

      Journal of neurochemistry
    87. LEE CS; SCHULZER M; MAK EK; SNOW BJ; TSUI JK; CALNE S; HAMMERSTAD J; CALNE DB
      CLINICAL OBSERVATIONS ON THE RATE OF PROGRESSION OF IDIOPATHIC PARKINSONISM

      Brain
    88. SCHULZER M; LEE CS; MAK EK; VINGERHOETS FJG; CALNE DB
      A MATHEMATICAL-MODEL OF PATHOGENESIS IN IDIOPATHIC PARKINSONISM

      Brain
    89. GUTTMAN M; LEGER G; RECHES A; EVANS A; KUWABARA H; CEDARBAUM JM; GJEDDE A
      ADMINISTRATION OF THE NEW COMT INHIBITOR OR-611 INCREASES STRIATAL UPTAKE OF FLUORODOPA

      Movement disorders
    90. CUMMING P; LEGER GC; KUWABARA H; GJEDDE A
      PHARMACOKINETICS OF PLASMA 6-[F-18]FLUORO-L-3,4-DIHYDROXYPHENYLALANINE ([F-18]FDOPA) IN HUMANS

      Journal of cerebral blood flow and metabolism
    91. WIESE C; COGOLIGREUTER M; WEINREICH R; WINTERHALTER KH
      COMT INHIBITORS AND METABOLISM OF FLUORODOPA ENANTIOMERS IN AGGREGATING CELL-CULTURES

      Naunyn-Schmiedeberg's archives of pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/02/20 alle ore 09:02:43